[go: up one dir, main page]

AR048741A1 - Derivados de omega-carboxiaril difenil urea sustituida - Google Patents

Derivados de omega-carboxiaril difenil urea sustituida

Info

Publication number
AR048741A1
AR048741A1 ARP040102614A ARP040102614A AR048741A1 AR 048741 A1 AR048741 A1 AR 048741A1 AR P040102614 A ARP040102614 A AR P040102614A AR P040102614 A ARP040102614 A AR P040102614A AR 048741 A1 AR048741 A1 AR 048741A1
Authority
AR
Argentina
Prior art keywords
carboxiaril
difenil
omega
derivatives
urea replaced
Prior art date
Application number
ARP040102614A
Other languages
English (en)
Inventor
Jacques Dumas
Stephen Boyer
Bernd Riedl
Scott Wilhelm
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048741(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AR048741A1 publication Critical patent/AR048741A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)

Abstract

Un compuesto de formula (1), sales del mismo, prodrogas del mismo, metabolitos del mismo, composiciones farmacéuticas que contienen dicho compuesto, y el uso de dicho compuesto y composiciones para tratar enfermedades mediadas por raf, VEGFR, PDGFR, p38, y flt-3.
ARP040102614A 2003-07-23 2004-07-23 Derivados de omega-carboxiaril difenil urea sustituida AR048741A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48910203P 2003-07-23 2003-07-23
US54032604P 2004-02-02 2004-02-02

Publications (1)

Publication Number Publication Date
AR048741A1 true AR048741A1 (es) 2006-05-24

Family

ID=34107784

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040102614A AR048741A1 (es) 2003-07-23 2004-07-23 Derivados de omega-carboxiaril difenil urea sustituida
ARP110100168A AR079933A2 (es) 2003-07-23 2011-01-19 Formulaciones que comprenden omega-carboxiaril difenil urea sustituida con fluoro en combinacion con un agente anticancerigeno adicional para el tratamiento y la prevencion de una enfermedad hiperproliferativa.
ARP130102046 AR091405A2 (es) 2003-07-23 2013-06-11 Omega-carboxiaril difenil urea sustituida con fluoro y composiciones farmaceuticas que las contienen

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP110100168A AR079933A2 (es) 2003-07-23 2011-01-19 Formulaciones que comprenden omega-carboxiaril difenil urea sustituida con fluoro en combinacion con un agente anticancerigeno adicional para el tratamiento y la prevencion de una enfermedad hiperproliferativa.
ARP130102046 AR091405A2 (es) 2003-07-23 2013-06-11 Omega-carboxiaril difenil urea sustituida con fluoro y composiciones farmaceuticas que las contienen

Country Status (37)

Country Link
US (3) US8637553B2 (es)
EP (1) EP1663978B1 (es)
JP (2) JP4777887B2 (es)
KR (1) KR101139557B1 (es)
CN (2) CN1856469B (es)
AR (3) AR048741A1 (es)
AU (2) AU2004259760B9 (es)
BE (1) BE2013C067I2 (es)
BR (2) BR122016015715B8 (es)
CA (1) CA2532865C (es)
CL (1) CL2004001834A1 (es)
CR (1) CR10193A (es)
CY (2) CY1107094T1 (es)
DE (1) DE602004010407T2 (es)
DK (1) DK1663978T3 (es)
EA (1) EA010485B1 (es)
EC (1) ECSP066302A (es)
ES (1) ES2297490T3 (es)
FR (1) FR13C0060I2 (es)
HK (2) HK1093978A1 (es)
HR (1) HRP20060073B1 (es)
HU (1) HUS1300073I1 (es)
IL (1) IL173256A (es)
LU (1) LU92300I2 (es)
MA (1) MA27946A1 (es)
ME (1) ME00294B (es)
MY (1) MY142799A (es)
NO (1) NO335323B1 (es)
NZ (2) NZ580384A (es)
PL (1) PL1663978T3 (es)
PT (1) PT1663978E (es)
RS (1) RS52625B (es)
SI (1) SI1663978T1 (es)
TN (1) TNSN06020A1 (es)
TW (1) TWI341201B (es)
UA (1) UA84156C2 (es)
WO (1) WO2005009961A2 (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1474393A1 (en) 2002-02-11 2004-11-10 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
NZ562416A (en) * 2003-02-21 2009-02-28 Resmed Ltd Nasal mask assembly for sleep apnea treatment
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP2007511203A (ja) * 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
TW200529849A (en) * 2003-11-28 2005-09-16 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
AU2011244932B9 (en) * 2004-08-27 2014-06-12 Bayer Pharmaceuticals Corporation New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
DK1868579T3 (da) 2005-03-07 2011-01-10 Bayer Schering Pharma Ag Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
EP1886138A4 (en) * 2005-05-11 2009-04-15 Genetic Technologies Ltd PROCESS FOR ENRICHING FETTAL CELLS
MX2007014920A (es) * 2005-05-27 2008-04-09 Bayer Healthcare Ag Politerapia que comprende diarilureas para el tratamiento de enfermedades.
RU2007148266A (ru) * 2005-05-27 2009-07-10 Байер ХельсКер АГ (DE) Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
KR20080074974A (ko) * 2005-11-10 2008-08-13 바이엘 헬스케어 아게 당뇨병성 신경병증을 치료하기 위한 디아릴 우레아
US20100035888A1 (en) * 2005-11-10 2010-02-11 Bater Healthcare AG Diaryl Urea for Treating Pulmonary Hypertension
EP1962841A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating virus infections
WO2007068382A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating inflammatory skin. eye and/or ear diseases
CA2633411A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
CN101058561B (zh) * 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP2338488A1 (en) 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
PE20080943A1 (es) * 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8
WO2008030448A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
WO2008044688A1 (fr) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2081902A1 (en) * 2006-11-09 2009-07-29 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
JP2010516692A (ja) * 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
CA2675980C (en) * 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
ES2670423T3 (es) * 2007-07-25 2018-05-30 Eisai R&D Management Co., Ltd. Inhibidores de multicinasas para uso en el tratamiento de cáncer
WO2009021150A2 (en) 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
CL2008002786A1 (es) * 2007-09-20 2009-05-15 Novartis Ag Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2453234B1 (en) * 2007-10-29 2014-01-15 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
WO2009132397A1 (en) * 2008-05-01 2009-11-05 University Of South Australia Methods and agents for modulating the level and/or activity of hif-2 alpha protein
KR101922096B1 (ko) 2008-06-17 2018-11-27 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
JP2011525506A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア類
EP2296641A1 (en) * 2008-06-25 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
US9410956B1 (en) * 2008-08-01 2016-08-09 University Of South Florida Micro-RNA profiling in ovarian cancer
DK2326329T3 (en) 2008-08-04 2017-02-20 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
WO2010019701A2 (en) * 2008-08-14 2010-02-18 Concert Pharmaceuticals, Inc. Diaryl urea derivatives
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CN102516154B (zh) * 2008-09-19 2015-03-18 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
HRP20230315T1 (hr) 2009-04-06 2023-05-12 Wyeth Llc Režim liječenja raka dojke korištenjem neratiniba
US8410082B2 (en) 2009-05-22 2013-04-02 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
CN102190616B (zh) 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2015201426B2 (en) * 2010-04-15 2016-07-07 Bayer Healthcare Llc Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
CA2796744A1 (en) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2011146725A1 (en) 2010-05-19 2011-11-24 Bayer Healthcare Llc Biomarkers for a multikinase inhibitor
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US20130183268A1 (en) * 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CA2812744A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012041987A1 (en) * 2010-10-01 2012-04-05 Bayer Pharma Aktiengesellschaft Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
WO2012129448A1 (en) 2011-03-23 2012-09-27 The Regents Of The University Of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2012162025A1 (en) * 2011-05-20 2012-11-29 President And Fellows Of Harvard College Methods of selecting cancer patients for treatment with n,n'-diarylurea compounds and n,n'-diarylthiourea compounds
EP2726059A1 (en) 2011-06-28 2014-05-07 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing regorafenib
US10441577B2 (en) 2011-07-08 2019-10-15 Helmholtz Zentrum Fuer Infektionsforschung Medicament for treatment of liver cancer
EP2543372A1 (en) * 2011-07-08 2013-01-09 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for the treatment of liver cancer
KR101374530B1 (ko) * 2011-07-14 2014-03-14 연세대학교 원주산학협력단 디에틸스틸베스트롤을 함유하는 심혈관 질환의 예방 또는 치료용 조성물
KR101909433B1 (ko) * 2011-12-02 2018-10-18 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 키나제 저해제의 부작용 저감제
CN103169720B (zh) * 2011-12-21 2016-12-07 张雅珍 蒽环类抗生素及其可药用盐在治疗视网膜静脉阻塞中的用途
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
AU2013269809B2 (en) 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
US20150165028A1 (en) * 2012-06-25 2015-06-18 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing cediranib
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
NZ705860A (en) * 2012-09-25 2018-07-27 Bayer Pharma AG Combination of regorafenib and acetylsalicylic acid for treating cancer
KR102057365B1 (ko) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 치환된 벤젠 화합물
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
US20160151380A1 (en) 2013-07-12 2016-06-02 The Regents Of The University Of California Therapies for diseases caused by arthropod-borne parasites
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN104736521B (zh) * 2013-09-12 2016-10-12 杭州普晒医药科技有限公司 瑞格非尼盐晶型及其制备方法和用途
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
WO2016038590A1 (en) 2014-09-12 2016-03-17 Mylan Laboratories Ltd Process for the preparation of crystalline form i of regorafenib
WO2016051422A2 (en) * 2014-09-29 2016-04-07 Msn Laboratories Private Limited Process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide and its polymorphs thereof
CN105566215B (zh) * 2014-10-17 2018-02-16 沈阳药科大学 一种瑞戈非尼的制备方法
CN105777625B (zh) * 2014-12-24 2020-05-22 浙江海正药业股份有限公司 一种制备4-（4-氨基-3-氟苯氧基）-n-甲基吡啶-2-甲酰胺的方法
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN104910067A (zh) * 2015-03-05 2015-09-16 南京工业大学 一锅法合成瑞戈非尼的方法
CN105218440A (zh) * 2015-09-07 2016-01-06 河南中医学院 一种高纯瑞戈非尼的制备方法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
US20190300484A1 (en) * 2016-01-18 2019-10-03 Natco Pharma Ltd An improved process for the preparation of regorafenib
WO2017134588A1 (en) 2016-02-04 2017-08-10 Shilpa Medicare Limited Process for the preparation of ibrutinib
AU2017227516B2 (en) * 2016-03-02 2022-03-03 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
WO2018035346A1 (en) * 2016-08-17 2018-02-22 Ichan School Of Medicine At Mount Sinal Kinase inhibitor compounds, compositions, and methods of treating cancer
JP7110232B2 (ja) 2017-04-18 2022-08-01 イーライ リリー アンド カンパニー フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物
DK3630112T3 (da) 2017-06-02 2024-04-22 Bayer Healthcare Llc Kombination af regorafenib og nivolumab til behandling af cancer
CN112041307B (zh) 2018-02-06 2024-02-09 伊利诺伊大学评议会 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
EP3802525A4 (en) 2018-05-30 2022-06-29 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
CN109796401B (zh) * 2019-04-04 2023-10-17 新乡双鹭药业有限公司 一种瑞戈非尼原料药的制备方法
GB201913123D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN112159351B (zh) * 2020-09-21 2021-12-07 广州南鑫药业有限公司 一种多靶点抗肿瘤药物的制备方法
IT202000022636A1 (it) 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
CN112842998A (zh) * 2021-01-19 2021-05-28 深圳市简一生物科技有限公司 一种瑞戈非尼分散剂及其制备方法
CN117233391A (zh) * 2023-08-28 2023-12-15 南方医科大学南方医院 一种用于预测胃癌免疫治疗和/或化疗疗效的生物标志物及其应用

Family Cites Families (475)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US502504A (en) 1893-08-01 Hermann thoms
DE487014C (de) 1927-10-23 1929-12-09 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Harnstoffderivaten
US1792156A (en) * 1928-01-17 1931-02-10 Gen Aniline Works Inc 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
DE511468C (de) 1928-01-18 1930-10-30 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 5-Chlor-2-amino-1-methoxybenzol
DE523437C (de) 1928-12-25 1931-05-05 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 5-Chlor- und 5-Brom-2-amino-1-alkyloxy- und 1-aralkyloxybenzolen
US2093265A (en) 1931-03-31 1937-09-14 Ici Ltd Process for the manufacture of diaryl ureas
US2046375A (en) 1931-06-04 1936-07-07 Ici Ltd p-halogen-omicron-alkoxy-aniline derivatives and process of preparing the same
US2288422A (en) * 1938-11-11 1942-06-30 Gen Aniline & Film Corp Mixed ureas
US2973386A (en) * 1943-01-05 1961-02-28 Harry A Weldon Purification of sym dichloro-bis (2, 4, 6-trichlorophenyl)urea
US2502504A (en) * 1946-10-18 1950-04-04 John L Botner Hogshead
DE925476C (de) 1950-04-29 1955-03-21 Variapat Ag Verfahren zur Herstellung von farblosen, wasserloeslichen, trifluormethyl- und sulfonsaeuregruppenhaltigen, aliphatischen oder aromatischen Carbonsaeure- bzw. Sulfonsaeurearyliden
US2683082A (en) 1950-12-09 1954-07-06 Ethyl Corp Nu-aryl-nu'-(p-hydroxyphenyl) ureas as antioxidants for petroleum hydrocarbon fuels
US2722544A (en) 1950-12-26 1955-11-01 Variapat Ag Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation
US2781330A (en) * 1953-02-09 1957-02-12 Monsanto Chemicals Rubber containing urea compound as an anti-exposure cracking agent
BE527017A (es) * 1953-03-06
US2745874A (en) * 1953-06-18 1956-05-15 Geigy Ag J R Insecticidal derivatives of diphenyl urea
GB771333A (en) 1953-12-22 1957-03-27 Geigy Ag J R Improvements relating to halogen substituted diphenyl urea and thiourea compounds and their use
NL193403A (es) * 1953-12-22 1924-02-17
GB828231A (en) 1955-10-20 1960-02-17 Geigy Ag J R Improvements relating to insecticidal compounds and their use
US2877268A (en) * 1956-12-24 1959-03-10 Monsanto Chemicals Substituted ureas
US2960488A (en) 1958-04-25 1960-11-15 Eastman Kodak Co Poly-alpha-olefins containing substituted ureas
NL254871A (es) 1959-08-14
NL277504A (es) 1961-04-21
CH479557A (de) 1961-09-11 1969-10-15 Wander Ag Dr A Verfahren zur Herstellung neuer mehrbasischer Verbindungen
US3200035A (en) 1962-06-01 1965-08-10 Ciba Ltd Treatment of synthetic products, especially synthetic fibers
US3284433A (en) 1963-07-17 1966-11-08 Merck & Co Inc 4-phenoxy-carbanilides
FR1457172A (fr) 1964-12-12 1966-10-28 Ferrania Spa Procédé pour la production d'images photographiques en couleurs et matériel photographique correspondant
FR90420E (es) 1965-06-09 1968-02-21
US3424762A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H Certain 3-ureidopyrrolidines
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3743498A (en) 1967-10-31 1973-07-03 Du Pont Method of selectively controlling undesirable vegetation
US3547940A (en) 1967-10-31 1970-12-15 Du Pont Substituted ureido isoxazoles
SE370866B (es) 1968-03-21 1974-11-04 Ciba Geigy Ag
DE1768244A1 (de) 1968-04-19 1971-10-14 Bayer Ag N-(2,2,4,4-Tetrafluor-1,3-benz-dioxanyl)-harnstoffe und Verfahren zu ihrer Herstellung
US3646059A (en) * 1969-05-05 1972-02-29 Du Pont Plant growth regulatory ureidopyrazoles
US3754887A (en) 1969-05-05 1973-08-28 Du Pont Ureidopyrazoles defoliants
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
BE754782A (fr) 1969-08-14 1971-02-12 May & Baker Ltd Derives du thiophene a action herbicide
US3823161A (en) 1970-05-07 1974-07-09 Exxon Research Engineering Co Aminothiophene derivatives
US3860645A (en) * 1973-05-23 1975-01-14 Givaudan Corp Bacteriostatic substituted carbanilides
JPS5031039A (es) 1973-07-27 1975-03-27
US4062861A (en) 1973-07-27 1977-12-13 Shionogi & Co., Ltd. 3-Isoxazolylurea derivatives
US4116671A (en) 1973-07-27 1978-09-26 Shionogi & Co., Ltd. 3-Isoxazolylcarbamate derivatives
US4212981A (en) 1973-07-27 1980-07-15 Shionogi & Co., Ltd. Process for preparing 3-isoxazolylurea derivatives
US4001256A (en) * 1973-12-26 1977-01-04 The Upjohn Company Pyridylalkyl phenyl ureas and their n-oxides
US3931201A (en) 1974-01-22 1976-01-06 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives
US4009847A (en) * 1974-04-17 1977-03-01 E. I. Du Pont De Nemours And Company 1-Tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas as antihypertensive agents
US3990879A (en) 1974-12-26 1976-11-09 Eli Lilly And Company Method of controlling aquatic weeds
US4111683A (en) 1975-06-27 1978-09-05 Chevron Research Company N-alkyl or alkoxy-N'-substituted hydrocarbyl urea
DE2637947C2 (de) 1976-08-24 1985-09-19 Bayer Ag, 5090 Leverkusen Tetrafluor-1,3-benzodioxanyl-benzoylharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
US4173637A (en) 1976-10-29 1979-11-06 Ishihara Sangyo Kaisha Ltd. N-Benzoyl-N'-pyridyloxy phenyl urea and insecticidal compositions thereof
JPS5840946B2 (ja) 1976-10-29 1983-09-08 石原産業株式会社 Ｎ−ベンゾイル−ｎ′−ピリジルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する殺虫剤
US4071524A (en) * 1976-11-08 1978-01-31 Riker Laboratories, Inc. Derivatives of urea
US4183854A (en) * 1976-11-10 1980-01-15 John Wyeth & Brother Limited Thiazole compound
US4042372A (en) 1976-11-19 1977-08-16 Eli Lilly And Company Substituted thiadiazolotriazinediones and method of preparation
DE2817449A1 (de) 1978-04-21 1979-10-31 Bayer Ag Mittel zur regulierung des pflanzenwachstums
GB1590870A (en) 1978-05-31 1981-06-10 Shionogi & Co N-(5-t-butyl-3-isoxazolyl) alkanamide derivatives having herbicidal activity
JPS5562066A (en) 1978-11-03 1980-05-10 Toshihiko Okamoto N-(2-substituted-4-pyridyl)-urea and thio urea, their preparation and plant growth regulator
DE2848330A1 (de) 1978-11-03 1980-05-14 Schering Ag Verfahren zur herstellung von 1,2, 3-thiadiazol-5-yl-harnstoffen
FI800559A (fi) 1979-03-14 1980-09-15 Hoffmann La Roche Urinaemnederivat
JPS55124763A (en) 1979-03-19 1980-09-26 Ishihara Sangyo Kaisha Ltd 5-trifluoromethyl-2-pyridone derivative
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4468380A (en) 1979-12-26 1984-08-28 Eli Lilly And Company Anticoccidial combinations comprising polyether antibiotics and carbanilides
US4410697A (en) 1980-01-25 1983-10-18 Reanal Finomvegyszergyar Process for the preparation of N-aryl-N'-(mono- or di substituted)-urea derivatives
DE3165743D1 (de) 1980-05-14 1984-10-04 Ciba Geigy Ag Phenylbenzoyl urea
DE3174885D1 (en) 1981-02-03 1986-07-31 Ici Plc Process for the extraction of metal values and novel metal extractants
US4526997A (en) 1981-05-06 1985-07-02 Doherty George O P O Anticoccidial combinations comprising polyether antibiotics and carbanilides
US4511571A (en) * 1981-10-20 1985-04-16 Ciba Geigy Corporation N-(2-Pyridyloxyphenyl)-N'-benzoyl ureas, pesticidal compositions containing same and pesticidal methods of use
US4473579A (en) 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
DE3211851A1 (de) * 1982-03-31 1983-10-06 Basf Ag Dihydrothiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPS58203957A (ja) * 1982-05-25 1983-11-28 Ube Ind Ltd 尿素誘導体の製法
AU1862083A (en) 1982-09-02 1984-03-08 Duphar International Research B.V. Tumor growth inhibitors
CA1254212A (en) * 1982-11-12 1989-05-16 Shiro Hirai Amine derivatives, salts thereof, process for preparing the same and an anti-ulcer agent containing the same
DE3305866A1 (de) 1983-02-19 1984-08-23 Basf Ag, 6700 Ludwigshafen Thiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4499097A (en) 1983-03-10 1985-02-12 American Cyanamid Company 2-(Pyridyl)imidazolyl ketones
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
CH663353A5 (de) 1984-03-28 1987-12-15 Joaquin Amat Larraz Mittel gegen krebs.
US4540566A (en) 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPS6193163A (ja) 1984-10-12 1986-05-12 Ishihara Sangyo Kaisha Ltd Ｎ−ベンゾイル−ｎ′−フエニルウレア系化合物、それらの製造方法並びにそれらを含有する抗癌剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) * 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
AU594098B2 (en) 1985-12-11 1990-03-01 Ishihara Sangyo Kaisha Ltd. N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation
EP0230400A3 (de) 1986-01-21 1990-02-14 Ciba-Geigy Ag N-3-(5-Trifluormethyl-pyridyl-2-oxy)-phenyl-N'-benzoylharnstoffe zur Bekämpfung von Helminthen an Nutztieren
JPS62185013A (ja) 1986-02-08 1987-08-13 Green Cross Corp:The 易吸収性医薬組成物
DE3612830A1 (de) 1986-04-16 1987-10-22 Basf Ag Thiadiazolylharnstoff enthaltendes mittel zur entblaetterung von pflanzen
DE3785507T2 (de) * 1986-07-31 1993-07-29 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
EP0262560A3 (en) 1986-09-29 1989-07-05 Ishihara Sangyo Kaisha, Ltd. Benzoyl urea compound
US4835180A (en) 1986-10-02 1989-05-30 Sterling Drug Inc. N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity
NZ221964A (en) * 1986-10-03 1990-03-27 Ishihara Sangyo Kaisha Benzoylurea compounds and insecticidal compositions
EP0264904A3 (en) 1986-10-23 1988-08-17 Ishihara Sangyo Kaisha, Ltd. Pharmaceutical compositions containing benzoyl urea derivatives
DE3636190A1 (de) * 1986-10-24 1988-04-28 Bayer Ag Verfahren zur herstellung von n,n-diaryl-harnstoffen
JPH06100808B2 (ja) 1987-05-28 1994-12-12 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法
ATE121742T1 (de) 1987-10-16 1995-05-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel.
DE3810382A1 (de) 1988-03-26 1989-10-12 Bayer Ag 5-amino-1-phenylpyrazole, verfahren sowie 5-halogen-1-phenylpyrazole als zwischenprodukte zu deren herstellung und ihre verwendung als herbizide
AU636853B2 (en) 1988-08-23 1993-05-13 Nutrasweet Company, The Substituted aryl ureas as high potency sweeteners
JPH0278699A (ja) 1988-09-12 1990-03-19 Green Cross Corp:The ベンゾイルウレア系化合物・アルブミン複合体
FR2662692B1 (fr) 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
FR2639636B1 (fr) 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
JPH02237922A (ja) 1989-01-24 1990-09-20 Green Cross Corp:The 抗ウィルス剤
EP0379915A1 (de) 1989-01-26 1990-08-01 Bayer Ag Substituierte Phenoxybenzonitril-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und Pflanzenwuchsregulatoren
JP3002204B2 (ja) * 1989-03-13 2000-01-24 株式会社東芝 時系列信号認識装置
US4973675A (en) 1989-04-13 1990-11-27 University Of Tennessee Research Center Hybrid nitrosoureidoanthracyclines having antitumor activity
JPH0395153A (ja) 1989-06-15 1991-04-19 Mitsubishi Kasei Corp ジフェニル尿素誘導体
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
IL95860A0 (en) 1989-10-13 1991-07-18 Ciba Geigy Ag Thienylthioureas,-isothioureas and-carbodiimides
EP0425443A1 (de) 1989-10-27 1991-05-02 Ciba-Geigy Ag Injizierbares parasitizides Mittel
DK40890D0 (da) 1990-02-16 1990-02-16 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
NZ238624A (en) * 1990-06-19 1994-08-26 Meiji Seika Co Pyridine derivatives, compositions, preparations and use thereof
GB9017892D0 (en) 1990-08-15 1990-09-26 May & Baker Ltd New compositions of matter
JP3108097B2 (ja) * 1991-01-21 2000-11-13 塩野義製薬株式会社 ３−ベンジリデン−１−カルバモイル−２−ピロリドン類縁体
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
NO921449L (no) 1991-04-17 1992-10-19 American Home Prod Karbamater av rapamycin
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5185358A (en) * 1991-06-24 1993-02-09 Warner-Lambert Co. 3-heteroatom containing urea and thiourea ACAT inhibitors
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
WO1993004170A1 (en) 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5254582A (en) 1992-02-05 1993-10-19 Eli Lilly And Company Antitumor compositions and methods
WO1993018028A1 (en) 1992-03-12 1993-09-16 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
JPH07503737A (ja) 1992-05-28 1995-04-20 フアイザー・インコーポレイテツド アシル補酵素ａ：コレステロールアシルトランスフェラーゼ（ａｃａｔ）の阻害剤としての新規なｎ−アリールおよびｎ−ヘテロアリール尿素誘導体
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
JP2717481B2 (ja) 1992-08-25 1998-02-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
CN2146707Y (zh) 1992-09-08 1993-11-17 华东冶金学院 高炉软水冷却系统检漏装置
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
US5512473A (en) 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
TW272942B (es) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK41193D0 (da) 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
DE4322806A1 (de) 1993-07-08 1995-01-12 Janich Gmbh & Co Vorrichtung zur Abdichtung zwischen zwei Anlagenteilen
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5871934A (en) 1993-09-17 1999-02-16 Smithkline Beecham Corporation Screening methods using cytokine suppressive anti-inflammatory drug (CSAID) binding proteins
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US6361773B1 (en) 1993-09-17 2002-03-26 Smithkline Beecham Corporation Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
CA2133815A1 (en) * 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
EP1306377A3 (en) 1993-11-08 2003-05-07 Smithkline Beecham Corporation Pyridyl-oxazoles and their use as cytokines inhibitors
JPH07141053A (ja) 1993-11-17 1995-06-02 Nec Niigata Ltd クロック発生回路
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CH686211A5 (de) * 1994-01-27 1996-02-15 Ciba Geigy Ag Motten- und Koferschutzmittel.
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
DE4412334A1 (de) 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5744362A (en) 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
WO1995033458A1 (en) 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
US5470882A (en) 1994-06-02 1995-11-28 Smithkline Beecham Corp. Anti-inflammatory compounds
US5447957A (en) 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
US5786362A (en) 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
EP0690344A1 (en) 1994-06-29 1996-01-03 Konica Corporation Silver halide color photographic light-sensitive material
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
FR2722319B1 (fr) 1994-07-08 1996-08-14 Thomson Csf Dispositif de visualisation couleurs
US5597719A (en) * 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
ES2180600T3 (es) 1994-10-19 2003-02-16 Novartis Ag Eteres de isosteros substrato de aspartato proteasa antivirales.
CA2161376C (en) 1994-10-27 2005-01-11 Toshiaki Minami Reversible multi-color thermal recording medium
DE69520951T2 (de) 1994-10-28 2001-11-22 Novozymes A/S, Bagsvaerd Verfahren zur chemischen ausrüstung von unlöslichen polymerfasern
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
FR2729567B1 (fr) * 1995-01-20 1997-06-13 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5814646A (en) 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
DE19512639A1 (de) 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
NO307879B1 (no) * 1995-09-18 2000-06-13 Sankyo Co Nye ureaderivater med ACAT-inhiberende aktivitet og farmasøytisk preparat inneholdende disse
SE510846C2 (sv) 1995-11-06 1999-06-28 Moelnlycke Health Care Ab Innerförpackning för i en yttre förpackning sterilförpackade bukdukar
WO1997017329A1 (fr) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
JP3844782B2 (ja) * 1995-12-28 2006-11-15 株式会社クレハ 新規なｎ―（無置換または置換）―４―置換―６―（無置換または置換）フェノキシ―２―ピリジンカルボキサミド又はチオカルボキサミド、その製造方法および除草剤
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6103692A (en) 1996-03-12 2000-08-15 The General Hospital Corporation Inhibiting protein interactions
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) * 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
EP0802187B1 (en) * 1996-04-15 2000-02-16 Takeda Chemical Industries, Ltd. Hydroxypyridine derivatives, their production and their pharmaceutical use
BR9708735A (pt) 1996-04-23 1999-08-03 Vertex Pharma Derivados de uréia como inibidores da enzina impdh
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
JPH09301858A (ja) 1996-05-13 1997-11-25 Senju Pharmaceut Co Ltd グルコン酸クロルヘキシジン安定化水性薬剤
DE69716424T2 (de) 1996-05-24 2003-02-20 Neurosearch A/S, Ballerup Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
EP0907362A4 (en) 1996-06-27 1999-12-01 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
KR20000022274A (ko) 1996-06-27 2000-04-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 Il-8 수용체 길항제
AU3499497A (en) 1996-06-27 1998-01-14 Smithkline Beecham Corporation Il-8 receptor antagonists
JP2000513360A (ja) * 1996-06-27 2000-10-10 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
WO1998017207A1 (en) 1996-10-21 1998-04-30 Synthes Ag Chur Surgical prosthetic device
AU4988997A (en) 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US5965573A (en) 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
AU746647B2 (en) 1996-11-15 2002-05-02 Ferring B.V. Guanylhydrazones useful for treating diseases associated with T cell activation
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
AU4966497A (en) 1996-11-18 1998-06-10 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
BR9807083A (pt) 1997-01-23 2000-04-18 Smithkline Beckman Corp Antagonistas ao receptor de il-8
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
JP2001512445A (ja) 1997-02-12 2001-08-21 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８レセプターアンタゴニスト
CN1254335A (zh) * 1997-04-04 2000-05-24 辉瑞产品公司 烟酰胺衍生物
ATE231839T1 (de) 1997-04-10 2003-02-15 Upjohn Co Polyaromatische antivirale zusammensetzungen
AU7080298A (en) 1997-04-25 1998-11-24 Takeda Chemical Industries Ltd. Triazine derivatives, their production and agrochemical composition
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
DE1019040T1 (de) 1997-05-23 2001-02-08 Bayer Corp., West Haven Hemmung von p38 kinase aktivität durch arylharnstoff
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
DE69839639D1 (en) 1997-05-23 2008-08-07 Bayer Pharmaceuticals Corp Raf kinase hemmer
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US20020156104A1 (en) 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
CA2294076A1 (en) 1997-06-27 1999-01-07 Kureha Kagaku Kogyo Kabushiki Kaisha 6-phenoxypicolinic acid, alkylidenehydrazide derivatives, process for producing the same, and herbicide
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
AU9802198A (en) 1997-10-21 1999-05-10 Pharmacia & Upjohn Company Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
PT1027328E (pt) 1997-10-31 2006-11-30 Aventis Pharma Ltd Anilidas substituídas
EP1028953A1 (en) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6018065A (en) 1997-11-10 2000-01-25 Advanced Technology Materials, Inc. Method of fabricating iridium-based materials and structures on substrates, iridium source reagents therefor
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
WO1999028305A1 (en) 1997-12-01 1999-06-10 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
US6635421B1 (en) 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US6174901B1 (en) * 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
SK282727B6 (sk) 1997-12-19 2002-11-06 Slovakofarma, A. S. 1,3-Disubstituované močoviny - inhibítory ACAT a spôsob ich prípravy
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
WO1999032455A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
TR200002616T2 (tr) 1997-12-22 2000-11-21 Bayer Corporation Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
WO1999032110A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
WO1999032111A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
HUP0101704A3 (en) 1997-12-22 2002-12-28 Bayer Corp Pittsburgh Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
EP1616865A1 (en) 1997-12-22 2006-01-18 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
WO1999033458A1 (fr) 1997-12-25 1999-07-08 Daiichi Pharmaceutical Co., Ltd. Composition medicinale pour administration percutanee
WO1999037604A2 (en) * 1998-01-21 1999-07-29 Zymogenetics, Inc. Dialkyl ureas as calcitonin mimetics
FR2774824B1 (fr) 1998-02-09 2000-04-28 Moving Magnet Tech Actionneur lineaire ameliore
CA2321458A1 (en) 1998-02-18 1999-08-26 Hilmar Meek Warenius Treating cancer
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6667340B1 (en) 1998-06-26 2003-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of phosphatidyl myo-inositol cycle
US6352977B1 (en) 1998-07-13 2002-03-05 Aventis Pharma Limited Substituted β-alanines
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US6383734B1 (en) 1998-09-30 2002-05-07 Advanced Research And Technology Institute, Inc. Method to determine inhibition of PAK3 activation of Raf-1
US6130053A (en) 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
CN1342077A (zh) 1998-11-06 2002-03-27 诺尔股份公司 抑制血管渗透性过高的形成
WO2000031238A2 (en) 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6147107A (en) 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
CN1326848C (zh) 1998-12-25 2007-07-18 帝国脏器制药株式会社 氨基吡唑衍生物
AU2725000A (en) * 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CN1183114C (zh) 1999-01-22 2005-01-05 麒麟麦酒株式会社 喹啉衍生物及喹唑啉衍生物
WO2000047577A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
JP2002537397A (ja) 1999-02-22 2002-11-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての多環ヘテロ環式誘導体
KR100709497B1 (ko) * 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 소염제로서 유용한 화합물 및 이의 제조방법
CA2361998C (en) 1999-03-12 2009-04-07 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
KR100652535B1 (ko) 1999-03-19 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 Ｉｍｐｄｈ 효소의 억제제
AU782353B2 (en) 1999-03-26 2005-07-21 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
US6140124A (en) 1999-04-06 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of P38 mitogen activated protein kinase expression
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
DE60009480T2 (de) 1999-05-05 2005-09-01 Aventis Pharma Ltd., West Malling Harnstoffe als modulatoren der zelladhäsion
WO2000069459A1 (en) 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
DE19927835A1 (de) 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
CN1151453C (zh) 1999-07-09 2004-05-26 酒井康江 取样函数波形数据发生装置
EP1200411B1 (en) 1999-07-09 2005-12-14 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds
CA2380389A1 (en) 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
ES2260036T3 (es) 1999-07-28 2006-11-01 Kirin Beer Kabushiki Kaisha Derivados de urea como inhibidores del receptor ccr-3.
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6372933B1 (en) 1999-08-26 2002-04-16 Smithkline Beecham Corporation Process for preparing certain phenyl urea compounds
EP1220688A1 (en) 1999-10-15 2002-07-10 The van Kampen Group, Inc. Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes
ES2292488T3 (es) 1999-11-16 2008-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de la urea, como agentes antiinflamatorios.
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
HUP0300359A2 (hu) 2000-02-07 2003-06-28 Abbott Gmbh & Co. Kg. 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2401665A1 (en) 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
CA2407063A1 (en) 2000-04-19 2001-10-25 Takeo Hirose Solid dispersion with improved absorbability
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2002007008A1 (en) 2000-04-28 2002-01-24 Ubink Cornelis Hubertus Johann Network procurement system
US6390102B1 (en) 2000-07-14 2002-05-21 General Electric Company Silicone compositions for personal care products and method for making
US7175844B2 (en) 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
CA2415131A1 (en) 2000-07-24 2002-01-31 Boehringer Ingelheim Pharmaceuticals, Inc. Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
RU2003105882A (ru) 2000-08-04 2005-01-20 Лома Линда Юниверсити Медикал Сентер (Us) Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях
AU8323701A (en) 2000-08-11 2002-02-25 John Cochran Inhibitors of p38
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
CA2386828C (en) 2000-08-17 2006-01-24 The Kitasato Institute Novel pseudoerythromycin derivatives
JP2004507526A (ja) 2000-08-31 2004-03-11 ファイザー・プロダクツ・インク ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
JP3768800B2 (ja) 2000-10-31 2006-04-19 キヤノン株式会社 画像形成装置
JP2004513935A (ja) 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
IL155820A0 (en) 2000-11-27 2003-12-23 Eric A Brill System, method and program for storing objects
EE200300247A (et) 2000-11-28 2003-10-15 Pfizer Products Inc. Isotiasool-4-karboksamiidi soolad ja nende kasutamine hüperproliferatsioonivastaste vahenditena
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
CN1492874A (zh) 2000-12-21 2004-04-28 大环内酯
KR100362390B1 (ko) 2000-12-29 2002-11-23 삼성전자 주식회사 화상형성장치의 현상기-토너 카트리지 조립체
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
WO2002059081A2 (en) 2001-01-26 2002-08-01 Kirin Beer Kabushiki Kaisha Urea derivatives as inhibitors of ccr-3 receptor
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
LT2269604T (lt) 2001-02-19 2016-11-10 Novartis Ag Inkstų solidinių navikų gydymas rapamicino dariniu
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
CA2434020A1 (en) 2001-03-07 2002-10-03 Telik, Inc. Substituted diarylureas as stimulators for fas-mediated apoptosis
US6525091B2 (en) 2001-03-07 2003-02-25 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
UY27225A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
WO2002083628A1 (en) 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzo-fused compounds
JP2005504727A (ja) 2001-04-13 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用なウレア化合物
EP1379505B1 (en) 2001-04-20 2007-02-28 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20030207914A1 (en) 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2445357A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
EP1392661A1 (en) 2001-05-16 2004-03-03 Boehringer Ingelheim Pharmaceuticals Inc. Diarylurea derivatives useful as anti-inflammatory agents
US6916814B2 (en) 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
SE0103838D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CA2468463C (en) 2001-12-03 2013-06-18 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
JP2005526008A (ja) * 2001-12-04 2005-09-02 オニックス ファーマシューティカルズ，インコーポレイティド 癌を処置するためのｒａｆ−ｍｅｋ−ｅｒｋ経路インヒビター
ES1050706Y (es) 2001-12-12 2002-08-16 Climastar Thermostone S L Convector electrico mejorado
AU2002353228B2 (en) 2001-12-21 2008-09-11 The Welcome Trust Genes
US20040096855A1 (en) 2001-12-24 2004-05-20 Michael Stratton Genes
WO2003060111A2 (en) 2001-12-24 2003-07-24 Catalyst Biomedica Limited Cancer-specific mutants of b-raf genes and uses thereof
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20050090474A1 (en) 2002-01-16 2005-04-28 Zvi Naor Methods and compositions for enhancing and inhibiting fertilization
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7928277B1 (en) 2002-02-11 2011-04-19 Cox Jr Henry Wilmore Method for reducing contamination
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP1474393A1 (en) 2002-02-11 2004-11-10 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
ES2311120T3 (es) 2002-08-27 2009-02-01 Merck Patent Gmbh Derivados de glicinamida como inhibidores de quinasa-raf.
MXPA05002493A (es) 2002-09-05 2005-05-27 Neurosearch As Derivados de diarilurea y su uso como bloqueadores del canal del cloro.
JP4690889B2 (ja) 2002-10-24 2011-06-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング メチレン尿素誘導体
AU2003291356A1 (en) 2002-11-06 2004-06-03 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
MXPA05005196A (es) 2002-11-15 2005-07-22 Novartis Ag Sistema de suministro de farmacos.
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
US20030232400A1 (en) 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
GB0317227D0 (en) 2003-07-23 2003-08-27 Pfizer Ltd Treatment of male sexual dysfunction
CA2516931C (en) 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004078128A2 (en) 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
ATE489379T1 (de) * 2003-02-28 2010-12-15 Bayer Healthcare Llc 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
PL377124A1 (pl) 2003-03-24 2006-01-23 Merck Patent Gmbh Pochodne oksamidu użyteczne jako inhibitory kinazy raf
US6896863B2 (en) 2003-04-01 2005-05-24 E. I. Du Pont De Nemours And Company Sodium cyanide process
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
BRPI0410913A (pt) 2003-06-05 2006-06-27 Warner Lambert Co benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
GB2403151A (en) 2003-06-27 2004-12-29 Intermark Medical Innovations A device for rectal lavage
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
WO2005005389A2 (en) 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
AU2004255340B2 (en) 2003-07-08 2008-05-01 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
WO2005016252A2 (en) 2003-07-11 2005-02-24 Ariad Gene Therapeutics, Inc. Phosphorus-containing macrocycles
US7691870B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
US7691886B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole derivatives as raf kinase inhibitors
US20060234931A1 (en) 2003-07-17 2006-10-19 Biggs William H Iii Treatment of diseases with kinase inhibitors
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
GB0317229D0 (en) 2003-07-23 2003-08-27 Pfizer Ltd Improved process
TW200523262A (en) 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
DE10334663A1 (de) 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
EA200600495A1 (ru) 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
EP1678123A1 (en) * 2003-10-15 2006-07-12 Bayer HealthCare AG Tetrahydro-naphthalene and urea derivatives
EP1680122A1 (en) 2003-10-16 2006-07-19 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for the treatment of cancer
EP1682126B1 (en) 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of raf kinase
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US20050171171A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
DE10352979A1 (de) 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
DE10354060A1 (de) 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
RU2006124421A (ru) 2003-12-09 2008-01-20 ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения
EP1692110A1 (en) 2003-12-10 2006-08-23 MERCK PATENT GmbH Diacylhydrazine derivatives
RU2006131045A (ru) 2004-01-30 2008-03-10 Мерк Патент ГмбХ (DE) Производные бисарилмочевины
JP2007530453A (ja) 2004-03-19 2007-11-01 ザ　ペン　ステート　リサーチ　ファウンデーション 黒色腫を治療するためのコンビナトリアル法および組成物
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ES2306216T3 (es) 2004-08-27 2008-11-01 Bayer Pharmaceuticals Corporation Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
WO2006027346A2 (en) 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
BRPI0515946A (pt) 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
CN101052619B (zh) 2004-09-29 2012-02-22 拜耳先灵制药股份公司 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法
PL1858877T3 (pl) 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
DK1868579T3 (da) 2005-03-07 2011-01-10 Bayer Schering Pharma Ag Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
RU2007148266A (ru) 2005-05-27 2009-07-10 Байер ХельсКер АГ (DE) Комбинированная терапия с использованием соединения диарилмочевины и ингибиторов pi3, akt-киназы или mtor (рапамицины) для лечения рака
MX2007014920A (es) 2005-05-27 2008-04-09 Bayer Healthcare Ag Politerapia que comprende diarilureas para el tratamiento de enfermedades.
EP1937837A2 (en) 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
WO2007039404A1 (en) 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
RU2395090C2 (ru) 2005-10-21 2010-07-20 БАЙЕР ХелсКер ЛЛСи Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
CA2627875A1 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Combinations comprising sorafenib and interferon for the treatment of cancer
EP1954272A2 (en) 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
JP2009515166A (ja) 2005-11-02 2009-04-09 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
US20100035888A1 (en) 2005-11-10 2010-02-11 Bater Healthcare AG Diaryl Urea for Treating Pulmonary Hypertension
CA2628847A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl ureas for treating pulmonary hypertension
EP1957069A2 (en) 2005-11-14 2008-08-20 Bayer Healthcare, LLC Treatment of cancers with acquired resistance to kit inhibitors
RU2008123406A (ru) 2005-11-14 2009-12-27 Байер Хелскеа эЛэЛСи (US) Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента
WO2007059155A1 (en) 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
EP2044053A2 (en) 2005-12-01 2009-04-08 Bayer Healthcare, LLC Urea compounds useful in the treatment of cancer
WO2007068383A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
US20090227637A1 (en) 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
EP1962841A1 (en) 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating virus infections
KR20080089410A (ko) 2005-12-21 2008-10-06 바이엘 헬스케어 아게 암 및 그 밖의 다른 장애의 치료에 유용한 치환된 피리미딘유도체
WO2007087575A2 (en) 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
CA2648106A1 (en) 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP2338488A1 (en) 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100143459A1 (en) 2006-11-09 2010-06-10 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2081902A1 (en) * 2006-11-09 2009-07-29 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
CA2672951A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
US8101773B2 (en) 2006-12-20 2012-01-24 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer
CA2675980C (en) 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
JP2010516692A (ja) 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
CN101669216B (zh) 2007-06-21 2011-05-18 夏普株式会社 光检测装置和具有其的显示装置
JP5076072B2 (ja) 2008-03-24 2012-11-21 矢崎総業株式会社 圧着端子、及びこの圧着端子を用いた圧着構造
EP2296641A1 (en) 2008-06-25 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
CA2741087A1 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
JP5077375B2 (ja) 2010-02-26 2012-11-21 井関農機株式会社 コンバイン

Also Published As

Publication number Publication date
US20130131122A1 (en) 2013-05-23
DE602004010407T2 (de) 2008-10-16
CA2532865C (en) 2013-08-06
HRP20060073B1 (hr) 2014-03-14
ECSP066302A (es) 2006-07-28
JP5505906B2 (ja) 2014-05-28
MY142799A (en) 2010-12-31
SI1663978T1 (sl) 2008-02-29
CY1107094T1 (el) 2012-10-24
AU2004259760A1 (en) 2005-02-03
UA84156C2 (ru) 2008-09-25
US20050038080A1 (en) 2005-02-17
HK1179259A1 (en) 2013-09-27
CA2532865A1 (en) 2005-02-03
CN102816113A (zh) 2012-12-12
NZ580384A (en) 2011-03-31
FR13C0060I1 (es) 2013-12-13
BR122016015715B8 (pt) 2021-05-25
AU2011201337A1 (en) 2011-04-14
KR101139557B1 (ko) 2012-04-30
CL2004001834A1 (es) 2005-06-03
MEP38308A (en) 2011-02-10
AR091405A2 (es) 2015-02-04
TWI341201B (en) 2011-05-01
IL173256A0 (en) 2006-06-11
PL1663978T3 (pl) 2008-04-30
TW200524604A (en) 2005-08-01
RS52625B (en) 2013-06-28
CN1856469A (zh) 2006-11-01
AU2004259760B2 (en) 2010-12-23
JP2011168599A (ja) 2011-09-01
LU92300I9 (es) 2019-01-16
AU2004259760B9 (en) 2011-02-03
JP4777887B2 (ja) 2011-09-21
HRP20060073A2 (en) 2006-06-30
EP1663978B1 (en) 2007-11-28
HUS1300073I1 (hu) 2017-04-28
DK1663978T3 (da) 2008-04-07
JP2006528196A (ja) 2006-12-14
NZ544920A (en) 2009-11-27
US20090192127A1 (en) 2009-07-30
CN102816113B (zh) 2015-05-13
BRPI0412219B8 (pt) 2021-07-27
KR20060052866A (ko) 2006-05-19
CY2013039I2 (el) 2015-11-04
CR10193A (es) 2008-09-30
CY2013039I1 (el) 2015-11-04
TNSN06020A1 (en) 2007-10-03
EP1663978A2 (en) 2006-06-07
BRPI0412219B1 (pt) 2018-02-06
RS20060037A (en) 2008-06-05
WO2005009961B1 (en) 2005-06-02
US8637553B2 (en) 2014-01-28
AR079933A2 (es) 2012-02-29
LU92300I2 (fr) 2013-12-30
WO2005009961A2 (en) 2005-02-03
ES2297490T3 (es) 2008-05-01
AU2011201337B2 (en) 2013-02-14
BR122016015715B1 (pt) 2020-10-20
EA200600317A1 (ru) 2006-06-30
IL173256A (en) 2011-03-31
CN1856469B (zh) 2013-03-06
MA27946A1 (fr) 2006-06-01
NO20060870L (no) 2006-04-07
DE602004010407D1 (de) 2008-01-10
HK1093978A1 (en) 2007-03-16
BRPI0412219A (pt) 2006-08-22
NO335323B1 (no) 2014-11-10
WO2005009961A3 (en) 2005-03-31
BE2013C067I2 (es) 2023-08-09
FR13C0060I2 (fr) 2014-04-11
PT1663978E (pt) 2008-02-15
EA010485B1 (ru) 2008-10-30
ME00294B (me) 2011-05-10

Similar Documents

Publication Publication Date Title
AR048741A1 (es) Derivados de omega-carboxiaril difenil urea sustituida
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
ECSP077271A (es) Derivados de pirimidina
UY29633A1 (es) Derivados de oxindol
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
ECSP077259A (es) Derivados de pirimidina
UY29607A1 (es) Compuestos quimicos
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
SE0401762D0 (sv) Novel compounds
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
SE0403085D0 (sv) Novel componds
UY29804A1 (es) Quinolinas de alquilnitrilo
UY29883A1 (es) Nuevos beta-agonistas que contienen indol, procedimientos para prepararlos, y su empleo como medicamentos

Legal Events

Date Code Title Description
FC Refusal